Disclosures under Regulation 46 of SEBI (LODR) Regulations, 2015
Details of Business
We are one of the largest corporate healthcare groups in AP and Telangana in terms of number of patients treated and treatments offered, according to the CRISIL Report. We provide multi-disciplinary integrated healthcare services, with a focus on primary secondary & tertiary care in Tier 2-3 cities and primary, secondary, tertiary and quaternary healthcare in Tier 1 cities. We operate 9 multi-specialty hospitals under the “KIMS Hospitals” brand, with an aggregate bed capacity of 3,064, including over 2,500 operational beds as of December 31, 2020, which is 2.2 times more beds than the second largest provider in AP and Telangana, according to the CRISIL report. We offer a comprehensive range of healthcare services across over 25 specialties and super specialties, including cardiac sciences, oncology, neurosciences, gastric sciences, orthopaedics, organ transplantation, renal sciences and mother & child care.
We have grown from a single hospital to a chain of multi-speciality hospitals through organic growth and strategic acquisitions under the leadership of Dr. Bhaskara Rao Bollineni, our founder and Managing Director, and Dr. Abhinay Bollineni, our Executive Director and CEO. Our first hospital in our network was established in Nellore in 2000 and has a capacity of approximately 200 beds. Our flagship hospital at Secunderabad is one of the largest private hospitals in India at a single location (excluding medical colleges), according to the CRISIL Report, with a capacity of 1,000 beds. We have significantly expanded our hospital network in recent years through our acquisitions of hospitals in Ongole in Fiscal Year 2017, Vizag and Anantapur in Fiscal Year 2019 and Kurnool in Fiscal Year 2020. Approximately one-third of our 3,064 beds were launched in the last four years. We have added over 880 beds, in aggregate, in our hospitals in Visakhapatnam (Vizag), Anantapur and Kurnool in Fiscal Years 2019 and 2020, and improved the overall bed occupancy rate in these hospitals from 71.83% to 80.49% in the same period. We strive to provide quality service to more patients, and we believe we have scope for additional patients and improved occupancy rates. We strategically focus on the southern India healthcare market where we have a strong understanding of regional nuances, customer culture and the mind-set of medical professionals and where there is significant and growing need for quality and affordable healthcare services. Each of our hospitals also has integrated diagnostic services and pharmacies that cater to our patients.
Dr. Bhaskara Rao Bollineni is a renowned cardiothoracic surgeon in India. He has over 27 years of experience in cardiothoracic surgery and has worked in several other leading medical institutions in the country. He started KIMS Nellore in the year 2000 with the vision to create a hospital system for his home state of AP that is capable of attracting top medical talent and providing high-quality care at affordable prices. Under his leadership, and that of Dr. Abhinay Bollineni, who joined KIMS in 2014, we have expanded into nine cities across AP and Telangana through a combination of greenfield, brownfield and acquisition-led expansion. Dr. Abhinay assumed our CEO position in 2019 and played a leadership role in expanding the KIMS’ network over the last 5 years, including in the launch of KIMS Kondapur and the acquisitions of our hospitals in Ongole, Vizag, Anantapur and Kurnool. Today, our current network consists of hospitals strategically located to serve the healthcare needs of AP and Telangana across urban Tier 1 cities such as Secunderabad and Hyderabad and more rural Tier 2-3 areas such as Vizag, Nellore, Rajahmundry, Srikakulam, Ongole, Anantapur and Kurnool. We believe our hospitals are also situated well to capture patient in-flow across AP and Telangana and from the neighboring states of Karnataka, Odisha, Tamil Nadu and parts of central India. We also believe that affordability and quality of healthcare services provided by us and our track record of building long-term relationships with medical professionals including our doctors, has enabled our growth and helped us build our ‘KIMS Hospitals’ brand.
Terms of Independent Directors
- Terms of Appointment of Independent Directors
Committees of Board
- Committees of the Board Audit Committee
1) Mr Saumen Chakraborty
2) Mr. G. Rajeswara Rao
3) Mr. Pankaj Vaish
4) Mr. Shantanu Rastogi
Nomination and Remuneration Committee
1) Mr. Pankaj Vaish
2) Mr. G. Rajeswar Rao
3) Mr. J. Venkata Ramudu
4) Mr. Shantanu Rastogi
CSR Committee
1) Dr. Bhaskar Rao Bollineni
2) Dr. Abhinay Bollineni
3) Mr. J. Venkata Ramudu
Stakeholders Relationship Committee
1) Mr. G. Rajeswara Rao
2) Mr. Kaza Ratna Kishore
3) Dr. Bhaskar Rao Bollineni
Policies
- Policy for Preservation of Documents
- Whistleblower Policy for Directors and Employees
- Policy for Determining Material Subsidiaries
- Policy on Code of Conduct
- Policy on Related Party Transactions
- Policy on Prevention of Insider Trading
- Policy of Nomination and Remuneration
- Policy on Diversity
- Policy for Determination of Materiality Threshold
- Policy on Familiarization of IDs
- Dividend Distribution Policy
- Policy on CSR
Financial Information
Board Meeting Intimation
FY 21-22
FY 22-23
Financial Results
FY 21-22
FY 22-23
Annual Report
Analysts Calls schedule, PPT & Transcripts
- Intimation regarding Investor call scheduled on 11.08.2022
- Intimation regarding Investor call scheduled on 08.09.2022
- Intimation regarding Investor visit scheduled on 22.09.2022
- Intimation regarding Investor call scheduled on 12.11.2022
- Intimation regarding Investor call scheduled on 30.11.2022
- Intimation regarding Investor call scheduled on 10.02.2023
-
Audio Recording of Investor call held on 11-08-2021
Recording Id: IIF0420210811136737 - Video Recording of Investor call held on 18-08-2021
- Transcripts of Investor Call held on 11-08-2021
-
Audio Recording of Earnings Investor call held on 11-11-2021
Recording Id: IIF0420211111138496 - Transcript of Earnings Investor Call held on 11-11-2021
-
Audio Recording of Investor call held on 20-05-2022
-
Transcript of Investor call held on 20-5-2022
-
Audio Recording of Investor call held on 11-08-2022
Recording Id: IIF0420220811142842 -
Transcript of Investor call held on 11-08-2022
-
Audio Recording of Investor call held on 12-11-2022
Recording Id: IIF0420221112144435 -
Transcript of Investor call held on 12-11-2022
-
Audio Recording of Investor call held on 10-02-2023
Recording Id: IIF0420230210145777 - Transcript of Earnings Investor Call held on 10-02-2023
-
Audio Recording of Investor call held on 19-05-2023
Recording Id: IIF0420230519147168 - Transcript of Earnings Investor Call held on 19-05-2023
Intimation of Schedule
FY 21-22
FY 22-23
PPT's
FY 21-22
FY 22-23
FY 23-24
Transcripts, Audio & Video Recordings
FY 21-22
FY 22-23
Credit Rating
Newspaper advertisements
FY 21-22
FY 22-23
FY 23-24
Subsidiary financials
FY 21-22
- KIMS Hospital Kurnool Pvt Ltd - for FY 21-22
-
KIMS Hospital Bengaluru Private Limited - for FY 21-22
- KIMS Hospital Private Limited - for FY 21-22
- KIMS Swastha Pvt Ltd - for FY 21-22
- Saveera Institute of Medical Sciences Pvt Ltd - for FY 21-22
- KIMS Hospital Enterprises Pvt Ltd - for FY 21-22
-
Iconkrishi Institute of Medical Sciences Pvt Ltd - for FY 21-22
FY 22-23
- Aurunodaya Hospitals Private Limited - for FY 22-23
- Iconkrishi Institute of Medical Sciences Pvt Ltd - for FY 22-23
- KIMS Hospital Bengaluru Private Limited - for FY 22-23
- KIMS Hospital Enterprises Pvt Ltd - for FY 22-23
- KIMS Hospital Kurnool Pvt Ltd - for FY 22-23
- KIMS Hospitals Private Limited -for FY 22-23
- KIMS Manavta Hospitals Pvt Ltd -for FY 22-23
- KIMS Swastha Private Limited - for FY 22-23
- Rajyalakshmi Healthcare Private Limited for FY 22-23
- Sarvejana Healthcare Private Limited -for FY 22-23
- Saveera Institute of Medical Sciences Pvt Ltd - for FY 22-23
- Spanv Medisearch Lifesciences Pvt Ltd -for FY 22-23
Secretarial Audit Report
Statement of Deviation/variation
Annual Return
Contact Details
-
Contact Us
Uma Shankar Mantha
GM - Legal & Company Secretary|
Address: 1-8-31/1, Minister Road,
Secunderabad, Telangana - 500 003|
Email: cs@kimshospitals.com
Phone: 04044186433
Disclosures under Regulation 62 of the SEBI (LODR) Regulations, 2015
Intimations filed by the Company
-
Related Party Transactions
-
Outcome of the Board Meeting
- Intimations under Regulation 30
- Closure of Trading Window Q1- FY 21
- Resignation Letter of Mr. Sandeep Naik
- Intimation under Regulation 30
- Intimation regarding Closure of Trading Window_Q3
- Intimation regarding appointment of Independent Director
- Intimation about KIMS-Mantava Acquisition
- Intimation regarding Closure of Trading Window_Q1-2022
- Kingsway Hospitals, Nagpur - Press Release
- Kingsway Hospitals, Nagpur - Definative Agreement
- Kingsway Hospitals, Nagpur - Acquisition
- Intimation regarding Closure of Trading Window_Q2-2022
- Intimation Regarding Acquisition of Shares
- Intimation Regarding Acquisition of Shares-KHEPL
- Intimation regarding Resignation of Mr. Shantanu Rastogi
- Intimation regarding Closure of Trading Window_Q3-2022
- Intimation of Board Meeting to be held on January 04, 2023
- Intimation Regarding the Sale of Step-down Subsidiary
- Intimation Regarding Acquisition of Shares-SHPL
- Intimation Regarding Trading Window Closure 31.03.2023
- Intimation Regarding Trading Window Closure 30.06.2023
- Intimation Regarding Acquistion of Shares-Sarvejana-2nd-Aug-2023
- Intimation towards the Acquisition of Shares by the Material Subsidiary-17-August-2023
- Intimation towards the Acquisition of Shares by the Material Subsidiary-11-September-2023
- Intimation towards the Acquisition of Shares by the Material Subsidiary - 16 September 2023
-
Corporate Governance Report
- FY 21-22
- Corporate Governance Report for the Quarter ended 30th June 2021
- Corporate Governance Report for the Quarter ended 30th September 2021
- Corporate Governance Report for the Quarter ended 31st December 2021
- Corporate Governance Report for the Quarter ended 31st March 2022
- FY 22-23
- Corporate Governance Report for the Quarter ended 30th June 2022
- Corporate Governance Report for the Quarter ended 30th September 2022
- Corporate Governance Report for the Quarter ended 31st December 2022
- Corporate Governance Report for the Quarter ended 31st March 2023
- FY 23-24
- Intimation under Regulation 74(5) of SEBI (Depository and Participants) Regulations, 2018
- FY 21-22
- 1st Quarter ended 30th June 2021
- 2nd Quarter ended 30th September 2021
- 3rd Quarter ended 31st December 2021
- 4th Quarter ended 31st March 2022
- FY 22-23
- 1st Quarter ended 30th June 2022
- 2nd Quarter ended 30th September 2022
- 3rd Quarter ended 31st December 2022
- 4th Quarter ended 31st March 2023
- FY 23-24
- Share Capital Audit
- FY 21-22
- Share Capital Audit for the quarter ended 30th September 2021
- Share Capital Audit for the quarter ended 31st December 2021
- Share Capital Audit for the quarter ended 31st March 2022
- FY 22-23
- Share Capital Audit for the quarter ended 30th June 2022
- Share Capital Audit for the quarter ended 30th September 2022
- Share Capital Audit for the quarter ended 31st December 2022
- Share Capital Audit for the quarter ended 31st March 2023
- FY 23-24